Stock upgrades today spotlight powerful signals

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  05 Dec 2025
 

•   AAL  
   
  0.00%
•   ALB  
   
  0.00%
•   ALK  
   
  0.00%
•   AMZN  
   
  0.00%
•   ARE  
   
  0.00%

$AAL Citi stepping in with a fresh Buy call on American Airlines adds renewed confidence to a cyclical name that thrives on improving travel demand and operational discipline, even with a modest upside forecast hinting at steady, not flashy, gains.

$ALB While sentiment around Albemarle has been volatile, the broader tone among analysts shifting more constructive on related names suggests lithium and specialty materials could be nearing a sentiment floor, setting the stage for a longer-term rebound narrative.

$ALK A bold Buy initiation on Alaska Air with nearly 50% implied upside is hard to ignore, signaling deep confidence in both cost control and improving passenger demand as airline profitability normalizes post-cycle.

$AMZN Rosenblatt sticking firmly with a Buy reinforces Amazon’s status as a long-term compounder, where cloud, ads, and retail efficiency continue to build a diversified growth machine aimed far beyond short-term headlines.

$ARE With multiple firms maintaining Outperform, Alexandria Real Estate stands out in the REIT space, as life sciences real estate continues to attract premium valuations and the 69% upside target makes it one of the more compelling reopening-style opportunities.

$AVGO The Positive rating on Broadcom highlights its critical role in AI infrastructure and enterprise networking, with stable upside showing this is more of a steady powerhouse than a speculative moonshot.

$AXGN Dual Buy ratings on Axogen suggest confidence in its medical innovation path, but the relatively small upside implies this is a story built on execution and patience rather than fast momentum.

$AZO A new Outperform initiation on AutoZone reflects strong pricing power and defensive positioning, making it an attractive candidate in a market still balancing growth with caution.

$BMY Sector Perform hints at stability for Bristol-Myers but muted upside reflects ongoing uncertainty around its pipeline and patent expirations, marking this as more of a hold-for-dividends name.

$BXP An upgrade to Overweight signals renewed optimism toward office REITs in key urban hubs, suggesting Boston Properties could benefit disproportionately if return-to-office trends strengthen.

$CAPR Despite a Buy label, the projected downside on Capricor makes this a higher-risk biotech play where sentiment and fundamentals are still wrestling for control.

$CAVA Initiating coverage with a Buy shows confidence in CAVA’s brand momentum and expansion strategy, positioning it as a fast-growth consumer name with clear runway.

$CHD Church & Dwight’s steady Buy rating underscores its defensive nature, appealing to investors who prefer consistent household-demand trends and reliable cash flow.

$CIEN Even with a Buy, the downside forecast for Ciena suggests near-term headwinds in networking demand, pointing to a potential longer consolidation phase.

$COST Outperform on Costco reinforces its fortress-like retail model and disciplined expansion, making it a dependable growth-plus-stability candidate even at premium valuations.

$CURB The upgrade to Overweight on Curbline brings attention to niche property exposure that could benefit as specialized retail continues outperforming traditional formats.

$CURV Torrid’s eye-popping upside potential paired with mixed ratings paints it as a speculative turnaround story that could reward brave contrarians.

$DAL A new Buy for Delta highlights confidence in its premium positioning and international network as travel trends stabilize into a more predictable growth cycle.

$DLTR Conflicting views on Dollar Tree reveal uncertainty about its turnaround path, keeping it in a tug-of-war between value hunters and skeptics.

$DSGX Stronger sentiment from Scotiabank boosts Descartes’ profile as a logistics-tech winner in an increasingly digitized supply chain world.

$FDX A Positive outlook signals FedEx remains a global commerce backbone, but limited upside makes this more of a steady performer.

$FIVE Mixed opinions suggest Five Below is balancing growth with margin pressures, keeping it on watchlists but not a clear conviction play for now.

$FLNC A sharp surge paired with upgraded targets puts Fluence in breakout territory, fueled by optimism in the clean energy storage theme.

$GE Initiation with a Positive view underlines confidence in GE’s streamlined future, where aviation and energy remain long-term industrial anchors.

$GENI Multiple Buy ratings frame Genius Sports as a high-upside digital data play linked to the expansion of legalized sports betting.

$GWRS The upgrade on Global Water Resources emphasizes the enduring value of water infrastructure in a world facing increasing scarcity stress.

$HOTH With a massive upside target, Hoth Therapeutics reads like a true biotech lottery ticket for risk-tolerant investors.

$HOVR Similar explosive potential in New Horizon Aircraft puts it in speculative tech territory where belief in the future of flight drives interest.

$HUM The shift to Buy at Jefferies signals renewed confidence in Humana’s strategy diversification within Medicare Advantage.

$INSP Outperform but with downside implies execution risk remains for Inspire Medical, making it a story to monitor rather than chase.

$KGS Solid Outperform sentiment reflects strength in energy services as natural gas demand stays resilient.

$KIM Upgrading Kimco Realty highlights improving valuation and dividend growth, appealing to income-focused investors with patience.

$LLY A slight downside despite Outperform suggests Lilly’s lofty valuation already prices in significant pipeline success.

$M Macy’s Buy rating clashes with downside estimates, pointing to a value trap or deep-value opportunity depending on execution.

$MDB Despite Buy ratings, near-term downside risk in MongoDB implies that expectations are being recalibrated in high-growth software.

$MRVL A resumed Buy on Marvell reinforces long-term confidence in its role in AI and data center expansion.

$MSFT Continued Buy calls combined with AI-powered product upgrades make Microsoft a cornerstone tech holding with both growth and pricing power.

$MU The Outperform label coupled with negative upside hints Micron is still navigating memory-cycle volatility.

$NCNO Strong upside projections and multiple positive ratings make nCino an appealing fintech recovery candidate.

$OKLO A surge driven by target hikes positions Oklo as a speculative nuclear-energy disruptor capturing investor imagination.

$OMAB The upgrade on Grupo Aeroportuario del Sureste shows modest but steady optimism in infrastructure tied to travel growth.

$ORCL A massive upside estimate and consistent Buy ratings put Oracle back in the spotlight as a quiet AI and cloud beneficiary.

$PL Buy sentiment for Planet Labs speaks to the long-term value of earth data and satellite analytics.

$PLD Limited upside but steady Outperform shows Prologis remains an anchor in global logistics real estate.

$PRKS Strong upside and Buy rating make United Parks & Resorts a reopening and leisure spending play.

$PVLA Fresh Buy initiation on Palvella signals early-stage optimism and speculative interest in its therapeutic pipeline.

$QCOM Reaffirmed confidence in Qualcomm reflects its successful pivot into AI, automotive, and IoT markets beyond smartphones.

$S A maintained Buy for SentinelOne shows trust in its cybersecurity vision even as short-term outlook softens.

$SKWD Strong upside and Outperform suggest Skyward Specialty is gaining traction in niche insurance markets.

$SNOW Nearly unanimous support across firms confirms Snowflake as a key data infrastructure bet, even with limited short-term upside.

$STKL Initiation with Buy places SunOpta on the radar as an emerging player in plant-based and natural foods.

$TJX Consistent Outperform ratings demonstrate TJX’s resilience in value retail as consumers seek deals.

$TNGX A new Buy for Tango Therapeutics makes it a compelling biotech growth watchlist name.

$TOL An upgrade to Overweight ahead of earnings highlights Toll Brothers as a premium housing play with strong demand dynamics.

View All Headlines